The
global Acinetobacter pneumonia therapeutics market comprises treatment options
targeting the deadly Acinetobacter baumanni pathogen, one of the top priority
bacterial pathogens according to the WHO. Antimicrobial therapies such as
polymyxins, carbapenems, ampicillin-sulbactam, tetracyclines treat the disease
by inhibiting bacterial growth. However, emerging antimicrobial resistance
poses a grave challenge.
The
Global Acinetobacter Pneumonia Therapeutics Market is estimated to be valued at
US$ 614.9 MN in 2024 and is expected
to exhibit a CAGR of 5.8 % over the
forecast period 2024 To 2031.
Key Takeaways
Key players operating in the
Global
Acinetobacter Pneumonia Therapeutics Market Demand are Pfizer Inc.,
Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG,
Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutical.
Growing rates of hospital-acquired infections and increasing prevalence of
multi-drug resistant Acinetobacter strains are driving the demand for novel
drugs. Moreover, rising geriatric population and investments in R&D of
novel antimicrobials will contribute to market expansion. Key players are
focusing on developing combination therapies and monoclonal antibodies to
counter antimicrobial resistance.
Market Key Trends
The key trend in the global Acinetobacter pneumonia therapeutics market is the
increasing antimicrobial resistance. Over-prescription and misuse of front-line
drugs have led to resistant Acinetobacter strains. There is an urgent need for
novel treatment options beyond polymyxins and carbapenems which are facing
resistance quickly. Pipeline candidates in combination with monoclonal
antibodies and those targeting virulence are promising alternatives being
evaluated in clinical trials. However, developing new drugs is a major
challenge due to low financial incentives and need for novel mechanisms to
combat evolving resistance mechanisms in Acinetobacter.
Porter’s Analysis
Threat of new entrants: High barriers for new entrants with high R&D and
clinical trial costs.
Bargaining
power of buyers: Small number of established players limits bargaining power of
buyers.
Bargaining
power of suppliers: Suppliers hold lower bargaining power due to availability
of substitute materials from other suppliers.
Threat
of new substitutes: Moderate threat as new antibiotics can be developed but
substitutes face same development challenges.
Competitive rivalry: Intense competition between
major players to gain higher market share through new drug launches and
acquisitions.
Geographical Regions
North America accounts for the largest share of the global Acinetobacter
pneumonia therapeutics market, in terms of value, followed by Europe. This is
attributed to high healthcare spending and rising prevalence of nosocomial
infections coupled with antibiotic resistance in the region. Asia Pacific is
expected to witness the fastest growth during the forecast period owing to
increasing expenditure on healthcare, rising awareness regarding treatment, and
improving healthcare infrastructure in emerging countries.
Another fastest growing region for this market is Latin America. Factors such
as increasing penetration of health insurance, rise in aging population, and
growth in healthcare expenditure are favoring the market growth in the region.
Countries such as Brazil, Mexico are expected to offer lucrative opportunities
for players in the coming years
Comments
Post a Comment